Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value
$241.55+1.18 (+0.49%)
Close on Nov 13, 2026Market cap $15.68BP/E 78.7Yield –
Jazz Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Jazz Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was 4.4%. For fiscal 2025 it was -8.3%, against 13.8% the year before. The highest annual figure on record is 49.2% in fiscal 2012.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -8.3% | −22.1 |
| FY2024 | Dec 31, 2024 | 13.8% | +2.9 |
| FY2023 | Dec 31, 2023 | 10.8% | +16.9 |
| FY2022 | Dec 31, 2022 | -6.1% | +4.5 |
| FY2021 | Dec 31, 2021 | -10.7% | −20.7 |
| FY2020 | Dec 31, 2020 | 10.1% | −14.1 |
| FY2019 | Dec 31, 2019 | 24.2% | +0.6 |
| FY2018 | Dec 31, 2018 | 23.6% | −6.5 |
| FY2017 | Dec 31, 2017 | 30.1% | +3.5 |
| FY2016 | Dec 31, 2016 | 26.7% | +1.8 |
| FY2015 | Dec 31, 2015 | 24.9% | +19.9 |
| FY2014 | Dec 31, 2014 | 5.0% | −19.8 |
| FY2013 | Dec 31, 2013 | 24.8% | −24.5 |
| FY2012 | Dec 31, 2012 | 49.2% | +3.3 |
| FY2011 | Dec 31, 2011 | 45.9% | +27.0 |
| FY2010 | Dec 31, 2010 | 18.9% | +24.2 |
| FY2009 | Dec 31, 2009 | -5.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -38.9% | −61.2 |
| Q2 FY2026 | Jun 30, 2026 | 16.0% | +84.7 |
| Q1 FY2026 | Mar 31, 2026 | 27.4% | +37.7 |
| Q4 FY2025 | Dec 31, 2025 | 17.0% | −0.6 |
| Q3 FY2025 | Sep 30, 2025 | 22.3% | +1.9 |
| Q2 FY2025 | Jun 30, 2025 | -68.7% | −85.2 |
| Q1 FY2025 | Mar 31, 2025 | -10.3% | −8.7 |
| Q4 FY2024 | Dec 31, 2024 | 17.6% | +8.3 |
| Q3 FY2024 | Sep 30, 2024 | 20.4% | +5.3 |
| Q2 FY2024 | Jun 30, 2024 | 16.5% | +5.6 |
| Q1 FY2024 | Mar 31, 2024 | -1.6% | −9.4 |
| Q4 FY2023 | Dec 31, 2023 | 9.3% | +34.1 |
| Q3 FY2023 | Sep 30, 2023 | 15.1% | +17.2 |
| Q2 FY2023 | Jun 30, 2023 | 10.9% | +7.2 |
| Q1 FY2023 | Mar 31, 2023 | 7.8% | +7.6 |
| Q4 FY2022 | Dec 31, 2022 | -24.8% | −20.8 |
| Q3 FY2022 | Sep 30, 2022 | -2.1% | +4.2 |
| Q2 FY2022 | Jun 30, 2022 | 3.7% | +52.0 |
| Q1 FY2022 | Mar 31, 2022 | 0.2% | −19.8 |
| Q4 FY2021 | Dec 31, 2021 | -3.9% | −24.0 |
| Q3 FY2021 | Sep 30, 2021 | -6.3% | −31.0 |
| Q2 FY2021 | Jun 30, 2021 | -48.3% | −68.7 |
| Q1 FY2021 | Mar 31, 2021 | 20.1% | +49.6 |
| Q4 FY2020 | Dec 31, 2020 | 20.0% | +7.3 |
| Q3 FY2020 | Sep 30, 2020 | 24.7% | +5.6 |
| Q2 FY2020 | Jun 30, 2020 | 20.4% | −28.6 |
| Q1 FY2020 | Mar 31, 2020 | -29.5% | −46.3 |
| Q4 FY2019 | Dec 31, 2019 | 12.7% | −20.8 |
| Q3 FY2019 | Sep 30, 2019 | 19.0% | −12.8 |
| Q2 FY2019 | Jun 30, 2019 | 49.0% | +30.6 |
| Q1 FY2019 | Mar 31, 2019 | 16.8% | +6.4 |
| Q4 FY2018 | Dec 31, 2018 | 33.5% | −19.7 |
| Q3 FY2018 | Sep 30, 2018 | 31.8% | +16.4 |
| Q2 FY2018 | Jun 30, 2018 | 18.4% | −8.3 |
| Q1 FY2018 | Mar 31, 2018 | 10.3% | −12.7 |
| Q4 FY2017 | Dec 31, 2017 | 53.2% | +23.8 |
| Q3 FY2017 | Sep 30, 2017 | 15.4% | – |
| Q2 FY2017 | Jun 30, 2017 | 26.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 23.0% | – |
| Q4 FY2016 | Dec 31, 2016 | 29.4% | – |
See a number that looks wrong?